Model of effect of magnesium prophylaxis on frequency of torsades de pointes in ibutilide-treated patients

American Journal of Health-System Pharmacy

Volumn 61, Issue 7, 2004, Pages 685-688

  Coleman, Craig I ^a,b   Kalus, James S ^c,d   Caron, Michael F ^e   Kluger, Jeffrey ^f,g,h   White, C Michael ^b,g,i  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d HENRY FORD HOSPITAL   (United States)

^e UNIVERSITY OF RHODE ISLAND   (United States)

^f Arrhythmia Service

^g HH   (United States)

^h UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

ⁱ Neurogenetics Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IBUTILIDE; MAGNESIUM SULFATE; SOTALOL; ANTIARRHYTHMIC AGENT; MAGNESIUM; SULFONAMIDE;

ARTICLE; CALCULATION; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HUMAN; MONTE CARLO METHOD; PRIORITY JOURNAL; PROPHYLAXIS; PROTECTION; QT INTERVAL; RANK SUM TEST; TORSADE DES POINTES; AGED; COMPARATIVE STUDY; FEMALE; MALE; MIDDLE AGED; UNITED STATES;

AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; FEMALE; HUMANS; MAGNESIUM; MALE; MIDDLE AGED; MONTE CARLO METHOD; SULFONAMIDES; TORSADES DE POINTES; UNITED STATES;

EID: 3042698830     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/61.7.685     Document Type: Article

References (15)

1. Cropp JS, Antal EG, Talbert RL. Ibutilide: a new class III antiarrhythmic agent. Pharmacotherapy. 1997; 17:1-9.
2. Corvert (ibutilide fumerate) package insert. Kalamazoo, MI: Pharmacia; 2002.
3. Lazzara R. Antiarrhythmic drugs and torsade de pointes. Eur Heart J. 1993; 14 (suppl H):88-92.
4. Dunn AB, White CM, Reddy P et al. Efficacy and cost analysis of ibutilide. Ann Pharmacother, 2000; 34:1233-7.
5. Tzivoni D, Banai S, Schuger C et al. Treatment of torsade de pointes with magnesium sulfate. Circulation. 1988; 77: 392-7.
6. White CM, Xie J, Chow MS et al. Prophylactic magnesium to decrease the arrhythmogenic potential of class III anti-arrhythmic agents in a rabbit model. Pharmacotherapy. 1999; 19:635-40.
7. Caron MF, Kluger JK, Tsikouris JP et al. Effects of intravenous magnesium sulfate on the QT interval in patients receiving ibutilide. Pharmacotherapy. 2003; 23:296-300.
8. Kalus JS, Spencer AP, Tsikouris JP et al. The impact of prophylactic i.v. magnesium on the efficacy of ibutilide for conversion of atrial fibrillation or flutter. Am J Health-Syst Pharm. 2003; 60:2308-12.
9. Betapace AF (sotalol hydrochloride) package insert. Wayne, NJ: Berlex Laboratories; 2001.
10. Ambrose PG, Grasela DM. The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. Diagn Microbiol Infect Dis. 2000; 38:151-7.
11. Funck-Brentano C, Jaillon P. Rate-corrected QT interval: techniques and limitations. Am J Cardiol. 1993; 72:17B-22B.
12. Burmaster DE, Anderson PD. Principles of good practice for the use of Monte Carlo techniques in human health and ecological risk assessments. Risk Anal. 1994; 14:477-81.
13. Haverkamp W, Breithardt G, Camm AJ et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J. 2000; 21:1216-31.
14. Moss AJ, Schwartz PJ, Crampton RS et al. The long QT syndrome. Prospective longitudinal study of 328 families. Circulation. 1991; 84:1136-44.
15. Walker AM, Szneke P, Weatherby LB et al. The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada. Am J Med. 1999; 107:356-62.